|
Post by porkini on Oct 4, 2017 20:59:16 GMT -5
As mentioned before / by who I forgot .. why isn't monomeric highlighted in the labeling in every which way ! Is it that that science is just understood ! Find that hard to believe . That person suggested/ THE ONLY MONOMERIC INSULIN ON THE SHELF , to differentiate itself .. what am I missing in what could be a great marketing opportunity. Also FAISP so slow to get going and so long a tail..they claim less hypo's..and Mannkind is Faster in and faster out...less hypo's then FAISP when used with a basal..and the basal is the blame..no hypos using Afrezza alone in a meal study even when nothing was ate...doubt FAISP will try that study any time soon HA! FIASP? Maybe FIASPO.
|
|
|
Post by kc on Oct 5, 2017 0:25:30 GMT -5
If you were Large Pharma...... How would you value SABOTAGE a potential drug/delivery system that could disrupt current therapy for one of the largest subsets of the industry and potentially change current uber profitable algorithms of treatment. Concurrently, how do you value SABOTAGE a delivery system that was able to accomplish this which could be used on perhaps tens or hundreds of drugs improving onset and action? Place regulatory barriers intended to slow progression of advancement of the drug. Cast dispersion on the efficacy and safety of the drug. Partner and take control without ever marketing a single ad about the drug. Impose expansion and future contractual obligations for supply. With control, market only to the smallest subset of the patient population. Withdraw support leaving company with few assets, extremely diluted shareholders letting market forces free to continue siege. Significantly reduce the patent life of intellectual property making the product less valuable. Force ultimate Bankruptcy and pick up the pieces. Am I cynical? Of course, I am a MNKD shareholder! Have you ever witnessed a drug/deliver system with such potential ignored by BP? Have you ever witnessed such a concerted effort in financial blogs and pundits to discredit such a product? Is it a perfect product, no. But it works and provides benefits not seen with competitive products. Time will also show that it will decrease morbidity and mortality in PWD. Thats what it is all about! I'm cynical but hopeful since we are still standing, and I am impressed so far by the actions and success of management. In the end and when successful, this will be written as a real life David vs Goliath story! I really feel Matt doesn’t get the recognition he deserves stepping into the CEO role when he did. He set a lot of the positive things happening now in motion. His claim of an “EPIC turnaround” is feeling more and more like reality. His comment about “position of strength” referenced the superior performance of Afrezza, not the financial position of the corporation at the time. I am with you! I hope that one day in the postmortem of how the turnaround took place we find that Matt had a big role in the turnaround. I believe he was a good man but we need somebody stronger and thankful we had Mike Castagna there ready to make the turn around.
|
|
|
Post by itellthefuture777 on Oct 5, 2017 0:46:13 GMT -5
I really feel Matt doesn’t get the recognition he deserves stepping into the CEO role when he did. He set a lot of the positive things happening now in motion. His claim of an “EPIC turnaround” is feeling more and more like reality. His comment about “position of strength” referenced the superior performance of Afrezza, not the financial position of the corporation at the time. I am with you! I hope that one day in the postmortem of how the turnaround took place we find that Matt had a big role in the turnaround. I believe he was a good man but we need somebody stronger and thankful we had Mike Castagna there ready to make the turn around. Phython Mike..crushes shorts for breakfast...daily...Slams Thor's hammer shooting lighting into the clouds at night...he's a world shaker..and am grateful of the wisdom of the board..an exemplar choice! Al would be proud!
|
|
|
Post by sayhey24 on Oct 5, 2017 5:31:59 GMT -5
If I were BP, more specifically, if I were Ollie Brandicourt and if those redacted pages do not contain a buy-out agreement which is still viable, I am not sure I would have slept last night or the night before or the night before that.
If I was Ollie I would call in all the smart guys who told me the future was Toujeo and to take all the money budgeted for afrezza and spend it on Toujeo and Ondou instead of doing the follow-up studies Al always wanted. I would ask these smart guys what now and probably end it with you are all fired.
Unless he makes a move soon, he appears to be doomed. This is hopefully the biggest pharma blunder of all time.
|
|
|
Post by sportsrancho on Oct 5, 2017 5:39:53 GMT -5
If I were BP, more specifically, if I were Ollie Brandicourt and if those redacted pages do not contain a buy-out agreement which is still viable, I am not sure I would have slept last night or the night before or the night before that. If I was Ollie I would call in all the smart guys who told me the future was Toujeo and to take all the money budgeted for afrezza and spend it on Toujeo and Ondou instead of doing the follow-up studies Al always wanted. I would ask these smart guys what now and probably end it with you are all fired. Unless he makes a move soon, he appears to be doomed. This is hopefully the biggest pharma blunder of all time. Yes.......I had a long conversation with someone about this exact subject last week:-) It should be interesting ..
|
|
|
Post by agedhippie on Oct 5, 2017 6:23:06 GMT -5
As mentioned before / by who I forgot .. why isn't monomeric highlighted in the labeling in every which way ! Is it that that science is just understood ! Find that hard to believe . That person suggested/ THE ONLY MONOMERIC INSULIN ON THE SHELF , to differentiate itself .. what am I missing in what could be a great marketing opportunity. Also FAISP so slow to get going and so long a tail..they claim less hypo's..and Mannkind is Faster in and faster out...less hypo's then FAISP when used with a basal..and the basal is the blame..no hypos using Afrezza alone in a meal study even when nothing was ate...doubt FAISP will try that study any time soon HA! It's an urban myth! Let me help you - here is a link to the study, read the results tab ( clinicaltrials.gov/ct2/show/NCT00747006) Let me quote from the Type 1 section of the study, " 50% carbohydrate load was administered but not completed due to all subjects having hypoglycemia, 0% carbohydrate load was deemed unsafe by PI"
|
|
|
Post by itellthefuture777 on Oct 5, 2017 6:35:57 GMT -5
Also FAISP so slow to get going and so long a tail..they claim less hypo's..and Mannkind is Faster in and faster out...less hypo's then FAISP when used with a basal..and the basal is the blame..no hypos using Afrezza alone in a meal study even when nothing was ate...doubt FAISP will try that study any time soon HA! It's an urban myth! Let me help you - here is a link to the study, read the results tab ( clinicaltrials.gov/ct2/show/NCT00747006) Let me quote from the Type 1 section of the study, " 50% carbohydrate load was administered but not completed due to all subjects having hypoglycemia, 0% carbohydrate load was deemed unsafe by PI" www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mannbehaves much like normal pancreatic insulin does. Normal people don't get hypos, and people taking Afrezza don't either, even if they dose and don't eat. How is that possible? Other insulins create an enormous period of hypoglycemia because there's an excess of insulin after you've digested your meal. What happens is that if you eat a meal on regular insulins, Lantus and Humalog for example, 80% of the insulin remains in your body for up to 10-12 hours after your meal, which causes hypoglycemia. With Afrezza, there's no complex meal titration. You take a set amount, matched to your body mass and insulin resistance, determined with your doctor. You take that same amount every time you eat a meal. Then it's not important whether you eat 50 grams of carbs or 100 grams or even zero. Afrezza essentially "turns off glucogenesis" so no glucose is secreted from the liver in reaction to food. Our trial studies are showing that patients are having no more glucose highs than normal non-diabetic people, and no more lows. That sounds pretty magical. Does this work for Type 2s only, or is it an option for Type 1s now taking basal and bolus insulin? Both could use it. Afrezza is for prandial control — mealtime only - not basal doses. For about 70% of Type 2s, all you'll need is a regular set dose of Afrezza. This will work for everyone except the "late-stage" Type 2s, who will need to take basal insulin as well. It's different for Type 1's because there's a very big therapeutic window for them; their insulin needs are so differing. They can use Afrezza to cover meals, yes, but they'll still have the issue that if they dose and don't eat anything, they'll get hypo, and if they eat a large meal, they'll need a larger dose. The advantage for all patients is that they won't have to do carb counting or anything, because Afrezza does not have to be so precisely matched to food intake.
|
|
|
Post by itellthefuture777 on Oct 5, 2017 6:42:57 GMT -5
It's an urban myth! Let me help you - here is a link to the study, read the results tab ( clinicaltrials.gov/ct2/show/NCT00747006) Let me quote from the Type 1 section of the study, " 50% carbohydrate load was administered but not completed due to all subjects having hypoglycemia, 0% carbohydrate load was deemed unsafe by PI" www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mannbehaves much like normal pancreatic insulin does. Normal people don't get hypos, and people taking Afrezza don't either, even if they dose and don't eat. How is that possible? Other insulins create an enormous period of hypoglycemia because there's an excess of insulin after you've digested your meal. What happens is that if you eat a meal on regular insulins, Lantus and Humalog for example, 80% of the insulin remains in your body for up to 10-12 hours after your meal, which causes hypoglycemia. With Afrezza, there's no complex meal titration. You take a set amount, matched to your body mass and insulin resistance, determined with your doctor. You take that same amount every time you eat a meal. Then it's not important whether you eat 50 grams of carbs or 100 grams or even zero. Afrezza essentially "turns off glucogenesis" so no glucose is secreted from the liver in reaction to food. Our trial studies are showing that patients are having no more glucose highs than normal non-diabetic people, and no more lows. That sounds pretty magical. Does this work for Type 2s only, or is it an option for Type 1s now taking basal and bolus insulin? Both could use it. Afrezza is for prandial control — mealtime only - not basal doses. For about 70% of Type 2s, all you'll need is a regular set dose of Afrezza. This will work for everyone except the "late-stage" Type 2s, who will need to take basal insulin as well. It's different for Type 1's because there's a very big therapeutic window for them; their insulin needs are so differing. They can use Afrezza to cover meals, yes, but they'll still have the issue that if they dose and don't eat anything, they'll get hypo, and if they eat a large meal, they'll need a larger dose. The advantage for all patients is that they won't have to do carb counting or anything, because Afrezza does not have to be so precisely matched to food intake. www.diabetesincontrol.com/an-exclusive-interview-with-al-mann-founder-and-ceo-mannkind-corp/
|
|
|
Post by agedhippie on Oct 5, 2017 6:43:31 GMT -5
It's an urban myth! Let me help you - here is a link to the study, read the results tab ( clinicaltrials.gov/ct2/show/NCT00747006) Let me quote from the Type 1 section of the study, " 50% carbohydrate load was administered but not completed due to all subjects having hypoglycemia, 0% carbohydrate load was deemed unsafe by PI" www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann... It's different for Type 1's because there's a very big therapeutic window for them; their insulin needs are so differing. They can use Afrezza to cover meals, yes, but t hey'll still have the issue that if they dose and don't eat anything, they'll get hypo, and if they eat a large meal, they'll need a larger dose. My point exactly! As a Type 1 if you take Afrezza for a meal and do not eat you will get a hypo. The study says so, and Al Mann says so - thank you.
|
|
|
Post by itellthefuture777 on Oct 5, 2017 6:53:46 GMT -5
www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mannbehaves much like normal pancreatic insulin does. Normal people don't get hypos, and people taking Afrezza don't either, even if they dose and don't eat. How is that possible? Other insulins create an enormous period of hypoglycemia because there's an excess of insulin after you've digested your meal. What happens is that if you eat a meal on regular insulins, Lantus and Humalog for example, 80% of the insulin remains in your body for up to 10-12 hours after your meal, which causes hypoglycemia. With Afrezza, there's no complex meal titration. You take a set amount, matched to your body mass and insulin resistance, determined with your doctor. You take that same amount every time you eat a meal. Then it's not important whether you eat 50 grams of carbs or 100 grams or even zero. Afrezza essentially "turns off glucogenesis" so no glucose is secreted from the liver in reaction to food. Our trial studies are showing that patients are having no more glucose highs than normal non-diabetic people, and no more lows. That sounds pretty magical. Does this work for Type 2s only, or is it an option for Type 1s now taking basal and bolus insulin? Both could use it. Afrezza is for prandial control — mealtime only - not basal doses. For about 70% of Type 2s, all you'll need is a regular set dose of Afrezza. This will work for everyone except the "late-stage" Type 2s, who will need to take basal insulin as well. It's different for Type 1's because there's a very big therapeutic window for them; their insulin needs are so differing. They can use Afrezza to cover meals, yes, but they'll still have the issue that if they dose and don't eat anything, they'll get hypo, and if they eat a large meal, they'll need a larger dose. The advantage for all patients is that they won't have to do carb counting or anything, because Afrezza does not have to be so precisely matched to food intake. www.diabetesincontrol.com/an-exclusive-interview-with-al-mann-founder-and-ceo-mannkind-corp/ It was canceled for busuness reasons..but there were zero hypos un all cases..In the later article Al says more about it
|
|